GoodRx (GDRX): Vanguard disaggregates holdings after Jan 12, 2026 realignment
Rhea-AI Filing Summary
GoodRx Holdings Inc filing an amendment to a Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares (0%) of Common Stock as shown in the amendment dated 03/13/2026. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Why does Vanguard report separate holdings in this Schedule 13G/A for GDRX?
The filing explains Vanguard completed an internal realignment on January 12, 2026, and under SEC Release No. 34-39538 certain subsidiaries now report beneficial ownership separately from The Vanguard Group, Inc.
Who signed the Schedule 13G/A amendment for Vanguard on GoodRx (GDRX)?
The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/27/2026, certifying the information in the filing.
Does the filing identify any entity holding more than 5% of GoodRx common stock?
No. The Schedule 13G/A states that no one other person's interest in the securities reported herein is more than 5%, and Vanguard reports ownership of 5 percent or less of the class.
What address is listed for The Vanguard Group in the GoodRx Schedule 13G/A?
The filing lists The Vanguard Group's principal business office as 100 Vanguard Blvd., Malvern, PA 19355, as provided in the Schedule 13G/A amendment.